2026-06-14T03:51:14Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/128882024-11-29T18:16:35Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597
Repisalud author Mavaddat, Nasim author Antoniou, Antonis C author Mooij, Thea M author Hooning, Maartje J author Heemskerk-Gerritsen, Bernadette A author Noguès, Catherine author Gauthier-Villars, Marion author Caron, Olivier author Gesta, Paul author Pujol, Pascal author Lortholary, Alain author Barrowdale, Daniel author Frost, Debra author Evans, D Gareth author Izatt, Louise author Adlard, Julian author Eeles, Ros author Brewer, Carole author Tischkowitz, Marc author Henderson, Alex author Cook, Jackie author Eccles, Diana author van Engelen, Klaartje author Mourits, Marian J E author Ausems, Margreet G E M author Koppert, Linetta B author Hopper, John L author John, Esther M author Chung, Wendy K author Andrulis, Irene L author Daly, Mary B author Buys, Saundra S author Caldes, Trinidad author Jakubowska, Anna author Simard, Jacques author Singer, Christian F author Tan, Yen author Olah, Edith author Navratilova, Marie author Foretova, Lenka author Gerdes, Anne-Marie author Roos-Blom, Marie-José author Van Leeuwen, Flora E author Arver, Brita author Olsson, Håkan author Schmutzler, Rita K author Engel, Christoph author Kast, Karin author Phillips, Kelly-Anne author Terry, Mary Beth author Milne, Roger L author Goldgar, David E author Rookus, Matti A author Andrieu, Nadine author Easton, Douglas F author Benitez, Javier funder Cancer Research UK (Reino Unido) funder NIH - National Cancer Institute (NCI) (Estados Unidos) funder United States Department of Health and Human Services funder Ministerio de Economía y Competitividad (España) funder Unión Europea. Comisión Europea. European Research Council (ERC) funder Norwegian EEA Financial Mechanism funder Hungarian Scientific Research Fund (Hungría) funder Ministry of Education, Youth and Sports (República Checa) funder MH CZ -DRO (MMCI) funder National Health and Medical Research Council (Australia) funder Australian National Breast Cancer Foundation funder Cancer Australia funder Unión Europea. Comisión Europea. H2020. ERA-NET funder Unión Europea. Comisión Europea. TRANSCAN funder Biotechnology and Biological Sciences Research Council (Reino Unido) funder Pink Ribbons Project funder Dutch Research Council (Holanda) funder Dutch Cancer Society (Holanda) funder Instituto de Salud Carlos III funder Deutsche Krebshilfe funder National Institute for Health Research (Reino Unido) funder Unión Europea. Comisión Europea. 7 Programa Marco funder Ministère du Développement économique, de Innovation et de Exportation (Canadá) funder Canadian Institutes of Health Research 2021-05-06T08:00:50Z 2021-05-06T08:00:50Z 2020-01-16 Breast Cancer Res. 2020;22(1):8. 10.1186/s13058-020-1247-4 1465-542X Breast cancer research : BCR 31948486 http://hdl.handle.net/20.500.12105/12888 The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO. eng Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. journal article 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 URL https://repisalud.isciii.es/bitstreams/c7716942-a7a0-4221-8357-3a61e9947d33/download File MD5 b3347bec916a3af1f77560984f3d6d13 945439 application/pdf Risk-reducingsalpingo-oophorectomy_2020.pdf URL https://repisalud.isciii.es/bitstreams/5c5f9861-e4b2-4973-b90b-64df86ad2d30/download File MD5 91e64b1898e2a161b55bca3050eecbd6 102341 application/vnd.openxmlformats-officedocument.wordprocessingml.document 13058_2020_1247_MOESM1_ESM.docx URL https://repisalud.isciii.es/bitstreams/537d4b1e-91f1-47d1-b5b3-96af122bb3fe/download File MD5 f2dace1f584e782434011d1d7f4089ed 59725 text/plain Risk-reducingsalpingo-oophorectomy_2020.pdf.txt URL https://repisalud.isciii.es/bitstreams/411cede7-2ebc-4558-9241-be570420badc/download File MD5 05e036d219391904ed5aa881e3e913c8 24898 text/plain 13058_2020_1247_MOESM1_ESM.docx.txt